0001209191-18-054525.txt : 20181009 0001209191-18-054525.hdr.sgml : 20181009 20181009163150 ACCESSION NUMBER: 0001209191-18-054525 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181008 FILED AS OF DATE: 20181009 DATE AS OF CHANGE: 20181009 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clayman Michael D. CENTRAL INDEX KEY: 0001597407 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36287 FILM NUMBER: 181114023 MAIL ADDRESS: STREET 1: C/O FLEXION THERAPEUTICS, INC. STREET 2: 10 MALL ROAD, SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Flexion Therapeutics Inc CENTRAL INDEX KEY: 0001419600 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: (781) 305-7777 MAIL ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-08 0 0001419600 Flexion Therapeutics Inc FLXN 0001597407 Clayman Michael D. C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803 1 1 0 0 President and CEO Common Stock 2018-10-08 4 M 0 14800 A 90082 D Common Stock 2018-10-08 4 F 0 6233 18.60 D 83849 D Common Stock 294383 I By the Michael D. Clayman 2006 Revocable Trust Common Stock 24600 I By the Michael D. Clayman Irrevocable Trust Common Stock 388683 I By Versant Development Fund III, LLC Restricted Stock Unit Award 2018-10-08 4 M 0 14800 0.00 D 2019-10-06 Common Stock 14800 14800 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares. On January 4, 2016, the reporting person was granted up to 66,600 restricted stock units. The amount and vesting of the shares under the restricted stock unit award was based on the achievement of certain milestones that were established at the time of the Compensation Committee's approval of the restricted stock unit award on December 17, 2015. On October 6, 2017, the Compensation Committee certified the achievement of a milestone under the restricted stock unit award resulting in the commencement of vesting of 44,400 shares as follows: 14,800 shares vested as of October 6, 2017, 14,800 shares vested as of October 6, 2018 and 14,800 shares vested as of October 6, 2019. /s/ Mark S. Levine, Attorney-in-Fact 2018-10-09